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Abstract
Purpose of Review Hypertension affects more than 30% of the world’s adult population and thiazide (and thiazide-like) diuretics
are amongst the most widely used, effective, and least costly treatments available, with all-cause mortality benefits equivalent to
angiotensin-converting enzyme inhibitors or calcium channel antagonists. A minority of patients develop thiazide-induced
hyponatremia (TIH) and this is largely unpredictable at the point of thiazide prescription. In some cases, TIH can cause
debilitating symptoms and require hospital admission. Although TIH affects only a minority of patients exposed to thiazides,
the high prevalence of hypertension leads to TIH being the most common cause of drug-induced hyponatremia requiring hospital
admission in the UK. This review examines current clinical and scientific understanding of TIH. Consideration is given to
demographic associations, limitations of current electrolyte monitoring regimens, clinical presentation, the phenotype evident
on routine clinical blood and urine tests as well as more extensive analyses of blood and urine in research settings, recent genetic
associations with TIH, and thoughts on management of the condition.
Recent Findings Recent genetic and phenotyping analysis has suggested that prostaglandin E2 pathways in the collecting duct
may have a role in the development of TIH in a subgroup of patients. Greater understanding of the molecular pathophysiology of
TIH raises the prospect of pre-prescription TIH risk profiling and may offer novel insights into how TIH may be avoided,
prevented and treated.
Summary The rising prevalence of hypertension and the widespread use of thiazides mean that further understanding of TIH will
continue to be a pressing issue for patients, physicians, and scientists alike for the foreseeable future.
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Introduction to the Role of Thiazides
in the Treatment of Hypertension
Hypertension is the most commonmodifiable cause of cardio-
vascular disease—the leading cause of mortality worldwide
[1, 2]. At least 30% of the UK adult population have hyper-
tension, and treatment consumes over a billion pounds per
year in NHS drug costs alone [1, 3]. Whilst the treatment of
hypertension is both evidence based and cost-effective [1],
most patients require multiple antihypertensive agents, side
effects are commonplace, and blood pressure control for many
remains poor [3]. The current therapeutic limitations are per-
haps not surprising since for most affected individuals we are
still unable to define either the molecular mechanisms driving
their hypertension or those leading to adverse effects from
antihypertensive treatment.
The association of hypertension with salt is intriguing how-
ever; sodium chloride intake correlates with the prevalence of
hypertension even in disparate populations [4], and sodium
restriction lowers blood pressure, especially in those already
hypertensive [5]. The physiological effects of salt on blood
pressure are not a simple function of intake but reflect the
balance of dietary salt ingestion and its excretion into the
urine. Regulation of sodium reabsorption from tubular filtrate
in the distal nephron has a marked effect on blood pressure
and although the amiloride-sensitive epithelial sodium (Na)
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channel (ENaC) has classically dominated research interest;
Na-Cl reabsorption via the thiazide-sensitive sodium chloride
co-transporter, NCC, is at least as important [6].
Thiazide and thiazide-like diuretics share a common
mechanism of action in the distal convoluted tubule of the
nephron by binding to the luminal side of the thiazide-
sensitive sodium chloride co-transporter, NCC. NCC is re-
sponsible for around 5–7% of renal sodium reabsorption
[7]. Commonly used examples of this group of medicines
include the thiazide diuretics bendroflumethiazide and hy-
drochlorothiazide, and the thiazide-like diuretics
indapamide and chlortalidone. Thiazide diuretics are potent
antihypertensive agents [1] and mimic the effects of loss of
function NCCmutations seen in the hypotensive Mendelian
syndrome of Gitelman [8]. Moreover, the heritable condi-
tion of hyperkalemic hypertension, Gordon syndrome
(GS), results from increased sodium reabsorption via
NCC and is effectively treated by low-dose thiazide di-
uretics and/or dietary sodium restriction [9].
Since the demonstration of their antihypertensive effect
in 1958 [10], thiazides have been widely used in the man-
agement of hypertension. Their benefits on all-cause mor-
tality are equal to those of angiotensin-converting enzyme
(ACE) inhibitors and calcium channel antagonists [11,
12]. Thiazide and thiazide-like diuretics continue to be
used first line in most countries in 2018 including the
USA [13] and Europe [14]. Their recent demotion to step
3 in UK hypertension guidance has been controversial [1,
15].
Despite the clinical success of thiazides, they are not a
panacea; they are often ineffective as monotherapy for
essential hypertension [1] and cause significant side ef-
fects of which hyponatremia is amongst the most impor-
tant, both clinically and scientifically as a paradigm of
dysregulation of sodium (and water) reabsorption in the
kidney [16]. Both the effectiveness of thiazide diuretics in
essential hypertension and in GS and their limitation in
the form of thiazide-induced hyponatremia (TIH) afford
valuable opportunities to probe the molecular pathophys-
iology of salt reabsorption in the distal nephron and to
inform the judicious use of thiazides in the treatment of
hypertension.
In this review, we will concentrate on two principal
sources of clinical data: a systematic review of all pub-
lished TIH cases up to 2013 [17••] and a subsequent se-
ries of 109 patients admitted to hospital with severe TIH
published in 2017 [18••]. The former has the advantage of
being a comprehensive and systematic literature review
which identified > 2800 patients with TIH, and the latter
is a large contemporary case series in which genetic and
extended phenotyping were undertaken, including assess-
ment of TIH patients after recovery to normonatremia as
an approximation of their likely baseline physiology.
Clinical Features of TIH
A minority of patients exposed to thiazides develop a suffi-
ciently reduced serum sodium concentration to be defined as
having TIH. However, because hypertension is such a preva-
lent condition, TIH is the most common cause of drug-
induced hyponatremia requiring admission to hospital [19•].
Classification of degrees of hyponatremia is inconsistent but
serum sodium 130–134 mM is often termed mild, 125–
130 mM moderate, and < 125 mM severe.
A systematic review and meta-analysis of all published
cases of TIH to 2013 found that the mean age of patients with
TIH was 75 (95% CI 73–77) years, 78% were women (95%
CI 74–82), and their mean body mass index was 25 (95% CI
20–30) kg/m2 [17••]. A subsequent large case series of 109
patients hospitalized with severe TIH broadly agreed with
this, with mean age 80 ± 9 years, 70% women, and BMI
25.7 ± 0.6 [18••]. Even when patients had recovered from
TIH and were normonatremic, their weight remained lower
than those of control patients who had not developed TIH,
suggesting that reduced body mass may be associated with
increased risk of development of TIH [18••]. Both systolic
and diastolic blood pressure was lower in acute TIH compared
to that in normonatremic controls and convalescent TIH cases.
The biological significance of gender is unclear since the
mean age of those with TIH puts them well beyond the men-
opause, perhaps implying a limited role for oestrogens.
Symptoms of TIH range from none or very mild to severe
and life threatening (Table 1). The severity of TIH symptoms
is likely to be related both to the rate of reduction in serum
sodium and the absolute degree of hyponatremia; patients who
develop a rapid reduction and very low absolute sodium con-
centration have the most severe symptoms; conversely, those
who develop hyponatremia slowly and with modest reduction
in absolute serum sodium concentration are more mildly
affected.
TIH has been reported with many types of thiazide and
thiazide-like diuretics [17••, 18••] and it is unclear whether
any particular thiazide medication is any more likely than
the others to cause TIH. Dose dependency is also unclear
although it is certainly possible to develop severe TIH at the
lowest prescribable dose and frequency of individual thiazide
or thiazide-like medicines.
Comorbidities and polypharmacy are important clinical
and scientific considerations in TIH since these are factors
which often affect the elderly population. The most frequent
comorbidities in TIH identified by systematic review and
meta-analysis were cardiovascular disease (49%, 95% CI 33
to 65%) and diabetes mellitus (27%, 95% CI 14 to 42%)
although there was substantial heterogeneity between studies
which was not explained by quality score, year of publication
or age of patient [17••]. The 2017 case series of TIH patients
broadly agreed with this having 17% of patients with treated
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diabetes mellitus, 19% with moderate renal impairment
(eGFR 30–60 mL/min), and 6% with treated hypothyroidism
[18••].
The commonest polypharmacy reported in the systematic
review of TIH includes angiotensin II receptor blockers
(ARBs) (59%, 95% CI 0 to 96%), angiotensin-converting en-
zyme (ACE) inhibitors (57%, 95% CI 29 to 83%), non-
thiazide diuretics (e.g., loop- and potassium-sparing diuretics)
(58%, 95% CI 19 to 91%), non-steroidal anti-inflammatory
drugs (NSAIDs) (33%, 95% CI 18 to 49%), and anti-
depressants (32%, 95% CI 19 to 47%). Whilst selective sero-
tonin reuptake inhibitors (SSRIs) are also known to be asso-
ciated with increased risk of developing hyponatremia, there
was insufficient data to determine what proportion of the anti-
depressant medication reported in TIH cases were SSRIs
[17••]. The 2017 case series of hospitalized TIH patients
broadly agreed with this polypharmacy data, with the most
commonly co-prescribed medications being ACEi or ARB,
non-thiazide diuretics, SSRIs (in 10%), aspirin, and
NSAIDS [18••]. It is of course not surprising that other anti-
hypertensive agents are commonly co-prescribed with thia-
zides, and both SSRIs and NSAIDs are also frequently used
in this age group of patients, and hence whether or not co-
prescription of these classes of groups increases TIH risk in
those prescribed thiazides remains unclear.
Time to Onset of TIH
The interval between first thiazide ingestion and onset of
hyponatremia in those developing TIH can be very variable.
A study of single dose thiazide rechallenge in patients who
had previously developed TIH showed that a reduction in
serum sodium and increase in urinary sodium excretion were
observed within hours (Fig. 1) [20•]. However, systematic
review of the time to TIH found that clinical presentation with
TIH occurred a mean of 19 (95% CI 8–30) days after starting
treatment [17••].
This makes it difficult to determine what the optimal timing
of a single post-thiazide initiation blood test for serum urea
and electrolytes (U&E) should be. There is little consistency
in the timing of this safety blood test but it is usually under-
taken within a week or two of thiazide initiation. Whether
undertaking more than one U&E blood test, e.g. at a few days
and at 2–4 weeks, would improve detection of TIH before
severe symptoms necessitate hospitalization is unclear. It is
important however that all patients started on a thiazide re-
ceive at least one serum electrolyte check within a few weeks
and it would seem prudent to undertake additional blood tests
if symptoms of TIH occur before or after the routine blood
test.
Routine Blood and Urine Tests in TIH Clinical
Care
It is usual to undertake blood and spot urine tests for U&E and
other potential causes of hyponatremia when assessing a pa-
tient with suspected TIH. Our systematic review found that
average mean trough serum U&E results in patients with TIH
were sodium 117 mM (95% CI 114 to 120), potassium
3.3 mM (95% CI 3.0 to 3.5), and reduced osmolality of
242 mOsm/kg (95% CI 238 to 246 mOsm/kg) [17••]. The
2017 case series of hospitalized TIH patients broadly agreed
with this with serum sodium 122 ± 0.6 mM, potassium 3.7 ±
0.06 mM and reduced osmolality of 255 ± 4 mOsm/kg [18••].
Table 1 Meta-analysis of the symptoms reported at presentation in patients with thiazide-induced hyponatremia [17••]. Prevalence estimates from
meta-analysis and confidence intervals are all expressed as proportions. Prop, proportion; Pop contributing population to the meta-analyses, number of
studies/total number of patients with the studies; CI, confidence interval; N, number of single case reports reporting the variable listed
Symptoms Prop 95% CI I2 (%) Pop Summary of case report data
Studies/patients N %
Falls 0.53 0.17 to 0.88 88 4/241 2 4
Fatigue 0.46 0.21 to 0.72 92 8/333 18 38
Weakness 0.45 0.32 to 0.58 49 14/247 13 27
Confusion 0.44 0.32 to 0.56 85 21/699 16 33
Nausea 0.37 0.24 to 0.50 78 13/394 10 21
Neurological symptoms 0.36 0.20 to 0.54 13 7/26 10 21
Vomiting 0.35 0.25 to 0.46 71 12/538 9 19
Dizziness 0.31 0.15 to 0.51 92 8/488 4 8
Unconsciousness 0.30 0.15 to 0.48 75 11/181 13 27
Seizures 0.19 0.08 to 0.34 84 9/394 10 21
Curr Hypertens Rep  (2018) 20:31 Page 3 of 6  31 
Plasma glucose was slightly higher in TIH patients than in
controls but at 7.6 ± 0.4 mM is insufficiently high to cause
pseudohyponatremia or to be the primary cause of
hyponatremia.
Spot urinary U&E in the systematic review demonstrated
less than maximal urinary dilution with urinary sodium con-
centration at 62 mM (95% CI 45 to 80 mM) and mean urine
osmolality greater than plasma at 400 mOsm/kg (95% CI 366
to 434 mOsm/kg) [17••]. The 2017 case series also showed
less than minimal spot urine concentration of 31 mM and
inappropriately concentrated urine with osmolality greater
than plasma at 366 mOsm/Kg [18••].
The phenotype of TIH is therefore similar to the criteria for
SIADH outlined by Bartter and Schwartz including (1) de-
creased plasma osmolality (< 275 mOsm/kg), (2) inappropri-
ately concentrated urine (> 100 mOsm/kg), (3) euvolemia on
clinical examination, and (4) elevated urine Na (> 20 mEq/L)
with (5) normal thyroid and adrenal function [21]. However,
as discussed below, antidiuretic hormone (ADH) is normal or
low in patients with TIH.
Further Blood and Urine Phenotyping in TIH
In addition to the routine blood and spot urine tests un-
dertaken in routine clinical care, TIH patients in the 2017
case series also underwent additional blood testing and
24 h urine collections both at the time of acute
hyponatremia and after recovery to normonatremia fol-
lowing thiazide cessation [18••]. Hyponatremic TIH pa-
tients were also hypochloridemic, which is perhaps unsur-
prising since the thiazide-sensitive NCC transports both
sodium and chloride. TIH cases also had a lower serum
concentration of magnesium, calcium, zinc, and vitamin D
relative to normonatremic controls. It is possible that the
lower concentration of the non-sodium chloride electro-
lytes could represent a dilution of blood from water reten-
tion, and this was supported by increased fractional urate
clearance, a marker of arterial blood volume expansion
[22, 23]. The lower vitamin D levels in TIH cases might
reflect the frailty of TIH patients who may be more lim-
ited in their diet and exposure to sunlight. Fortunately, all
of these parameters improved substantially after thiazide
cessation, although convalescent TIH cases showed per-
sistence of a milder degree of hypochloridemia and
hypozincemia relative to controls [18••].
TIH cases demonstrated an exaggerated free water reab-
sorption when taking thiazides compared to controls, which
also supports a volume-expanded, diluted state. The continued
production of urine which is more concentrated than plasma
and which contains more than minimal sodium salt is physio-
logically inappropriate in the context of acute hyponatremia.
Whilst 24 h urinary excretion of sodium and chloride was
lower in acute TIH cases than in controls and increased from
the acute state when convalescent, it is difficult to know
whether such data indicates reduced salt intake in acute TIH
cases given the dynamic pathophysiological state they are in.
Convalescent TIH cases had slightly lower 24 h sodium and
chloride excretion than controls but this was not statistically
significant. There remains the possibility that TIH cases could
have a slightly lower intake of dietary salt than controls but
this remains unclear.
Given the similarity in phenotype between SIADH and
TIH, antidiuretic hormone (ADH) was measured and was sur-
prisingly lower in acute TIH cases than in controls or conva-
lescent cases. The phenotype of TIH cases suggested ADH
excess but in fact they had less ADH than controls, raising the
question whether something other than ADH may be stimu-
lating distal nephron water absorption.
Fig. 1 TIH can occur rapidly and is accompanied by excessive saliuresis
[20•]. Rechallenge of 11 patients with previous TIH (closed circles),
young controls (open squares), and age-matched elderly controls (open
circles) with a single oral dose of hydrochlorothiazide 50 mg plus
amiloride 5 mg. Serum sodium fell within 6 h in TIH patients only (a)
(*P < 0.01) and this was accompanied by excessive saliuresis relative to
age matched controls (b) (**P < 0.01). Reproduced with permission from
Eitan Friedman, MD, et al., Thiazide-Induced Hyponatremia:
Reproducibility by Single Dose Rechallenge and an Analysis of
Pathogenesis. Annals of Internal Medicine, Jan 01, 1989 110
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Genetic Predisposition to TIH
Thiazide therapy does not meaningfully alter average serum
sodium concentration within the treated population with es-
sential hypertension, suggesting that there are defined sub-
groups of patients who are susceptible to substantial reduction
in sodium on exposure to thiazides. Genetic predisposition to
TIH is supported by a high degree of reproducibility on single
dose thiazide rechallenge where environmental factors such as
sodium intake were controlled [20•]. A priori, the molecular
mechanisms underlying predisposition to TIH must result in
either diminished sodium reabsorption, inappropriate water
retention or a combination of the two. That there may be
non-NCC effects of thiazides contributing to TIH may be
argued from the absence of significant hyponatremia in
Gitelman syndrome [8] or Gitelman-mimic animals carrying
a loss of function mutation in the NCC regulator Ste20
Proline-Alanine-rich Kinase (SPAK) [24].
A pilot genome-wide association study (GWAS) was under-
taken in a discovery cohort of 48 patients hospitalized with
severe TIH and compared to patients from the 1958 British
birth cohort [18••]. Given the limited number of cases available
a pre-defined cut off for signals of interest showing suggestive
association of P < 10−5 was used. In total, 17 SNPs within 14
regions were identified as showing association with TIH at this
level. The prostaglandin E2 (PGE2) transporter (PGT, coded by
the SLCO2A1 gene), was chosen for further study because TIH
has a phenotype resembling SIADH, and it was the candidate
with the best known function in regulating water reabsorption
in the collecting duct via the AQP2 pathway. Sequencing con-
firmed the presence of a non-synonymous variant encoding
p.A396T (rs34550074), which was in complete linkage dis-
equilibrium with the sentinel GWAS SNP rs4854769, and the
genetic association was replicated using a second cohort of TIH
cases hospitalized with severe TIH [18••].
Immunohistochemistry of human cadaveric kidneys con-
firmed that PGT was expressed in the collecting duct and co-
localized with AQP2. Using an in vitro cell expression system,
PGTcontaining the phospho-mimic p.A396E demonstrated loss
of function. This would be expected to reduce reuptake of PGE2
from the urinary lumen and indeed increased urinary PGE2 was
seen in TIH patients with the PGT p.A396T variant compared
to TIH patients who were wild type, suggesting that the PGT
variant may have a functional effect in patients. Differences in
urinary PGE2 resolved following thiazide cessation.
Taking these findings together, a hypothesis was proposed
in which the combined effect of thiazide-induced impairment
of renal free water generation, together with genetically deter-
mined PGE2-mediated increased water permeability of the
collecting ducts, produces a combination of natriuresis and
excessive water reabsorption sufficient to lead to a substantial
decline in serum sodium concentration and presentation with
severe TIH (Fig. 2).
Management of TIH
The treatment of patients with TIH involves a careful balance
between the desire to relieve symptoms by restoration of se-
rum sodium and the risk of central pontine myelinolysis
from overly rapid correction of serum sodium and other
more general risks associated with unnecessary parenteral
treatment. The balance of risks and benefits should be
made by the treating physician with each patient’s circum-
stances considered individually. We would advocate using
the cautious approach adopted for chronic hyponatremia
with a maximum desirable rise in serum sodium of ≤
10 mmol/l in the first 24 h and ≤ 8 mmol/l in each fol-
lowing 24 h. In frail, undernourished patients, it may be
prudent to be even more cautious.
Our experience of managing TIH has been that cessation of
the thiazide and avoidance of excessive water intake result in
recovery of serum sodium at a clinically acceptable rate of a
few millimoles per liter per day in most patients. Parenteral
infusion of saline under closely monitored conditions is usu-
ally reserved for TIH cases with severe or life-threatening
features. In support of this approach, an observational study
of thiazide -associated hyponatremia found that progressively
more aggressive strategies to elevate sodium in addition to
thiazide cessation (including fluid restriction, parenteral infu-
sion of normo- or hyper-tonic saline and the use of V2 antag-
onists such as tolvaptan) were found to be associated with
increased probability of overly rapid correction of serum so-
dium [25]. It is important that patients with TIH have a serum
electrolyte measurement after recovery to ensure that they are
truly normonatremic. If chronic hyponatremia persists after
thiazide withdrawal, then investigation for other causes of
hyponatremia may be appropriate.
Conclusion
Thiazide-induced hyponatremia is an important medical condi-
tion which is seen regularly in internal medicine and which
causes substantial morbidity to often elderly frail patients. At
present, the risk of developing TIH is largely unpredictable at
the point of thiazide initiation. TIH is also an interesting and
important condition scientifically as a relatively little studied par-
adigm of human sodium and water dysregulation which may
provide an opportunity to learn more about the molecular pro-
cesses underlying these essential aspects of renal physiology.
Pressing clinical issues include:
(1) What is the optimal timing of a blood electrolyte test
after starting thiazides, or should there be more than
one electrolyte check?
(2) Is it possible to identify a subgroup of patients at increased
risk of TIH by developing a risk score based on their age,
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gender, weight, baseline blood, and urine tests, and genet-
ic profile? If so, can this be used either to select alternative
antihypertensive treatment or to focus additional monitor-
ing if such patients are exposed to thiazides?
(3) What is the optimal management of patients with TIH?
There are also many scientific questions remaining
including:
(1) What causes TIH in those who do not carry the PGT
p.A396T mutation?
(2) What role do the other genetic associations identified
play in the pathophysiology of TIH?
(3) What effect do drugs which alter the production of PGE2
or which antagonize the EP4 receptor have on TIH
pathophysiology?
(4) Is the cause of TIH consistent across ethnicities?
Thiazides are used worldwide and yet most studies have
been in Caucasians to date
(5) What is the physiological response to non-thiazide di-
uretics in those with a history of TIH?
Given the effectiveness of thiazides in lowering blood pres-
sure and preventing cardiovascular disease and their very low
cost, it seems likely that thiazide-induced hyponatremia will
be an important long-term issue in medicine; there are a po-
tentially large number of patients who may benefit from great-
er understanding of this condition.
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